Medindia

X

BioIQ Transforms Corporate Wellness With Home Health Testing Programs and Workforce-Wide Results Analysis

Wednesday, August 27, 2008 General News J E 4
Advertisement
SANTA BARBARA, Calif., Aug. 26 BioIQ(http://www.bioiq.com), a leading provider of health data management services,has introduced a new generation of corporate wellness solutions(https://www.bioiq.com/m/wellness) that include at-home testing for employeesand analysis of aggregate health statistics for employers. Developed to workin conjunction with existing corporate wellness initiatives, BioIQ's programshelp organizations screen large numbers of employees and dependents quicklyand affordably to detect chronic diseases such as diabetes, pre-diabetes,heart disease, and cancer. BioIQ's biometric screening programs includeat-home test kits, online health assessments, live customer support, healthcoach follow-up, electronic health records, and a complete communications planfor encouraging participation with employees and dependents.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080826/LATU074)

"BioIQ is the first company to combine the convenience of home testingwith a proven program for engaging participants and following up withhigh-risk individuals via a complimentary health-coach service," said JustinBellante, CEO of BioIQ. "The entire process is managed as a single service:signing up participants, delivering test kits, presenting lab results, andsending reminders to keep people involved. We remove the barriers to gettingtested and give individuals convenient, practical resources for improvingtheir health."

If recent health statistics compiled by the U.S. Department of Health andHuman Services are any indication, BioIQ's end-to-end health screeningprograms couldn't have come along at a better time. According to a 2007 study,25 percent of America's workforce has cardiovascular disease, 26 percenttested positive for high blood pressure, 30 percent suffer from highcholesterol, 38 percent are overweight and 6 percent are diabetic.

In an effort to reverse these alarming statistics, two thirds of all U.S.companies offer wellness programs that include smoking cessation programs,nutrition advice and gym memberships. What's lacking in these programs is hardbiometric data that employees can use as a yardstick to measure improvement.Many physicians recommend an A1c or Fasting Glucose test to screen fordiabetes and a complete cholesterol panel to reveal an individual's risk forheart disease. BioIQ lets employees and dependents conduct these tests(https://www.bioiq.com/products) at home by supplying a few drops of blood toa unique sample platform. After dropping the samples in the mail they areprocessed by a certified laboratory.

BioIQ's biometric screening programs (https://www.bioiq.com/m/how) beginwith a complete health risk assessment to put test results into a personalizedcontext. Results are presented to participants via personal health dashboards,securely accessible through BioIQ's informative website. Participants receivepractical advice on prevention, risk factors, and lifestyle changes toencourage good health.

In addition to easy-to-understand lab reports, each participant receives adiscussion form to share with his or her physician. They can call a healthcoach via a toll-free number if they have questions. To culminate the program,BioIQ generates aggregate reports that enable HR managers to see which riskfactors are most prevalent within their member populations, and to makecorresponding adjustments to their health care programs.

About BioIQ

Based in Santa Barbara, Calif., BioIQ (http://www.bioiq.com) is a healthcare information technology company that develops and markets medicaldiagnostic solutions through corporate, institutional and direct-to-consumerchannels. Customers use BioIQ products to monitor or screen for diabetes,cancer, heart disease, kidney disease, thyroid disorder, osteoporosis, andother chronic health conditions.

SOURCE BioIQ
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Semafore Broadens Pipeline With Multi-Targeted Kin...
S
SF1126, Semafore's PI3 Kinase Inhibitor, Found to ...